NCT/Study#
NCT05289687 /
ECOG-EA9213
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
